HER2 and breast cancer stem cells

More than meets the eye

Hasan Korkaya, Max S. Wicha

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

The development of HER2 targeting agents has dramatically altered the natural history of HER2-positive breast cancer and is often cited as a prime example of the effectiveness of molecularly targeted therapy. Emerging data suggest that the remarkable clinical efficacy of these agents may be related to their ability to target the breast cancer stem cell (CSC) population. A new study suggests that the regulation of BCSCs by HER2 may extend to breast cancers that do not display HER2 gene amplification. In these tumors, HER2 is selectively expressed in the CSC population, and this expression is regulated by the tumor microenvironment. In mouse models, trastuzumab blocked growth of these HER2-negative tumors when administered in the adjuvant setting but had no effect on established tumors. These studies provide a potential biologic explanation for retrospective analysis of clinical trials, which surprisingly suggest that the clinical benefits of adjuvant trastuzumab may extend to women currently classified as HER2-negative. In addition to having significant implications for breast cancer therapy, these studies suggest the need to reevaluate the role of HER2 in regulating CSCs in other tumor types. Furthermore, these studies suggest that effective adjuvant therapies may need to target the CSC population.

Original languageEnglish (US)
Pages (from-to)3489-3493
Number of pages5
JournalCancer Research
Volume73
Issue number12
DOIs
StatePublished - Jun 15 2013

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Neoplasms
Population
erbB-2 Genes
Tumor Microenvironment
Gene Amplification
Natural History
Therapeutics
Clinical Trials
Growth
Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER2 and breast cancer stem cells : More than meets the eye. / Korkaya, Hasan; Wicha, Max S.

In: Cancer Research, Vol. 73, No. 12, 15.06.2013, p. 3489-3493.

Research output: Contribution to journalReview article

Korkaya, Hasan ; Wicha, Max S. / HER2 and breast cancer stem cells : More than meets the eye. In: Cancer Research. 2013 ; Vol. 73, No. 12. pp. 3489-3493.
@article{1e1d518fae4b437fb2b681aeca8eff2a,
title = "HER2 and breast cancer stem cells: More than meets the eye",
abstract = "The development of HER2 targeting agents has dramatically altered the natural history of HER2-positive breast cancer and is often cited as a prime example of the effectiveness of molecularly targeted therapy. Emerging data suggest that the remarkable clinical efficacy of these agents may be related to their ability to target the breast cancer stem cell (CSC) population. A new study suggests that the regulation of BCSCs by HER2 may extend to breast cancers that do not display HER2 gene amplification. In these tumors, HER2 is selectively expressed in the CSC population, and this expression is regulated by the tumor microenvironment. In mouse models, trastuzumab blocked growth of these HER2-negative tumors when administered in the adjuvant setting but had no effect on established tumors. These studies provide a potential biologic explanation for retrospective analysis of clinical trials, which surprisingly suggest that the clinical benefits of adjuvant trastuzumab may extend to women currently classified as HER2-negative. In addition to having significant implications for breast cancer therapy, these studies suggest the need to reevaluate the role of HER2 in regulating CSCs in other tumor types. Furthermore, these studies suggest that effective adjuvant therapies may need to target the CSC population.",
author = "Hasan Korkaya and Wicha, {Max S.}",
year = "2013",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-13-0260",
language = "English (US)",
volume = "73",
pages = "3489--3493",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - HER2 and breast cancer stem cells

T2 - More than meets the eye

AU - Korkaya, Hasan

AU - Wicha, Max S.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - The development of HER2 targeting agents has dramatically altered the natural history of HER2-positive breast cancer and is often cited as a prime example of the effectiveness of molecularly targeted therapy. Emerging data suggest that the remarkable clinical efficacy of these agents may be related to their ability to target the breast cancer stem cell (CSC) population. A new study suggests that the regulation of BCSCs by HER2 may extend to breast cancers that do not display HER2 gene amplification. In these tumors, HER2 is selectively expressed in the CSC population, and this expression is regulated by the tumor microenvironment. In mouse models, trastuzumab blocked growth of these HER2-negative tumors when administered in the adjuvant setting but had no effect on established tumors. These studies provide a potential biologic explanation for retrospective analysis of clinical trials, which surprisingly suggest that the clinical benefits of adjuvant trastuzumab may extend to women currently classified as HER2-negative. In addition to having significant implications for breast cancer therapy, these studies suggest the need to reevaluate the role of HER2 in regulating CSCs in other tumor types. Furthermore, these studies suggest that effective adjuvant therapies may need to target the CSC population.

AB - The development of HER2 targeting agents has dramatically altered the natural history of HER2-positive breast cancer and is often cited as a prime example of the effectiveness of molecularly targeted therapy. Emerging data suggest that the remarkable clinical efficacy of these agents may be related to their ability to target the breast cancer stem cell (CSC) population. A new study suggests that the regulation of BCSCs by HER2 may extend to breast cancers that do not display HER2 gene amplification. In these tumors, HER2 is selectively expressed in the CSC population, and this expression is regulated by the tumor microenvironment. In mouse models, trastuzumab blocked growth of these HER2-negative tumors when administered in the adjuvant setting but had no effect on established tumors. These studies provide a potential biologic explanation for retrospective analysis of clinical trials, which surprisingly suggest that the clinical benefits of adjuvant trastuzumab may extend to women currently classified as HER2-negative. In addition to having significant implications for breast cancer therapy, these studies suggest the need to reevaluate the role of HER2 in regulating CSCs in other tumor types. Furthermore, these studies suggest that effective adjuvant therapies may need to target the CSC population.

UR - http://www.scopus.com/inward/record.url?scp=84879092200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879092200&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0260

DO - 10.1158/0008-5472.CAN-13-0260

M3 - Review article

VL - 73

SP - 3489

EP - 3493

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 12

ER -